Medicus Pharma (MDCX) Short term Debt (2025)

Medicus Pharma (MDCX) reported Short term Debt of $5.2 million for Q4 2025, down 22.7% quarter-over-quarter from $6.8 million in Q3 2025.

Medicus Pharma (MDCX) Short term Debt (2025) Analysis & Trends

Medicus Pharma has reported Short term Debt for 1 years, with the latest figure at $5.2 million in Q4 2025.

For the quarter ending Q4 2025, Short term Debt changed N/A year-over-year to $5.2 million; the trailing twelve-month figure through Dec 2025 stood at $5.2 million (changed N/A YoY), and the FY2025 full-year result was $5.2 million, changed N/A from the prior year.
Short term Debt for Q4 2025 stood at $5.2 million, down from $6.8 million in the prior quarter.
The five-year high for Short term Debt was $6.8 million in Q3 2025, with the low at $4.7 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	93,699,046.73 Bn	93,699,041.77 Bn	7.76 Bn
2	Eli Lilly	1,012.06 Bn	1,006.77 Bn	16.22 Bn
3	Johnson & Johnson	560.67 Bn	538.62 Bn	15.96 Bn
4	AbbVie	402.20 Bn	392.85 Bn	10.78 Bn
5	Merck	298.59 Bn	292.94 Bn	12.09 Bn
6	Amgen	188.77 Bn	176.74 Bn	5.87 Bn
7	Gilead Sciences	160.22 Bn	152.49 Bn	5.52 Bn
8	Pfizer	148.19 Bn	135.42 Bn	-1.21 Bn
9	Bristol Myers Squibb	116.72 Bn	106.26 Bn	8.07 Bn
10	Medicus Pharma	6.05 Mn	6.15 Mn	-

Download Data